Clozapine and global cognition in schizophrenia

Journal of Clinical Psychopharmacology

Volumn 30, Issue 4, 2010, Pages 431-436

  Rajji, Tarek K ^a,b   Uchida, Hiroyuki ^a,c   Ismail, Zahinoor ^a,b,d   Ng, Wenzie ^e   Mamo, David C ^a,b   Remington, Gary ^a,d   Pollock, Bruce G ^a,b,f   Mulsant, Benoit H ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF LONDON   (United Kingdom)

^f ROTMAN RESEARCH INSTITUTE   (Canada)

Author keywords

clozapine; cognition; muscarinic; N desmethylclozapine; schizophrenia

Indexed keywords

CLOZAPINE; NORCLOZAPINE; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT;

ADULT; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; ANALOGS AND DERIVATIVES; COGNITION DISORDERS; CROSS-SECTIONAL STUDY; DOSE RESPONSE; DRUG EFFECTS; FACTUAL DATABASE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RECEPTORS, MUSCARINIC; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 77955166848     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181e69060     Document Type: Article

References (47)

1. Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: arewe measuring the Bright stuff[? Schizophr Bull. 2000;26:119-136.
2. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12:426-445.
3. Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001;158:518-526.
4. Fleischhacker WW. Clozapine: a comparison with other novel antipsychotics. Paper presented at: Meeting on Treatment-Resistant Schizophrenia and BeyondVCurrent Concepts and Future Prospects; July 8-9, 1998; London, England.
5. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophreniaVInternational Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60:82-91.
6. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry. 1994;36:717-725.
7. Daniel DG, Goldberg TE, Weinberger DR, et al. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Paper presented at: 147th Annual Meeting of the American Psychiatric Association; May 21-26, 1994; Philadelphia, PA.
8. Zahn TP, Pickar D, Haier RJ. Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophr Res. 1994;13:133-143.
9. Lindenmayer JP, Iskander A, Park M, et al. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. J Clin Psychiatry. 1998;59:521-527.
10. Gallhofer B, Bauer U, Lis S, et al. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol. 1996;6:S2-S20.
11. Grace J, Bellus SB, Raulin ML, et al. Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psychiatr Serv. 1996;47:41-45.
12. MeyerLindenberg A, Gruppe H, Bauer U, et al. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry. 1997;30:35-42.
13. Akdede BBK, Yagcioglu AEA, Alptekin K, et al. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. Paper presented at: 39th Turkish National Psychiatry Congress; October 14, 2003; Antalya, Turkey.
14. Fujii DEM, Ahmed I, Jokumsen M, et al. The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. J Neuropsychiatry Clin Neurosci. 1997;9:240-245.
15. Goldberg TE, Greenberg RD, Griffin SJ, et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry. 1993;162:43-48.
16. Hagger C, Buckley P, Kenny JT, et al. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry. 1993;34:702-712.
17. Harvey PD, Sacchetti E, Galluzzo A, et al. A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. Schizophr Res. 2008;105:138-143.
18. Hoff AL, Faustman WO, Wieneke M, et al. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology. 1996;15:361-369.
19. Krakowski MI, Czobor P, Nolan KA. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. J Clin Psychopharmacol. 2008;28:485-493.
20. Lee MA, Thompson PA, Meltzer HY. Effect of clozapine on cognitive function in schizophrenia. Paper presented at: Symposium-Clozapine 1994; February 25-26, 1994; Garden City, NY.
21. Lee MA, Jayathilake K, Meltzer HY. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr Res. 1999;37:1-11.
22. Meltzer HY, Bobo WV, Roy A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2008;69:274-285.
23. Purdon SE, Labelle A, Boulay L. Neuropsychological change in schizophrenia after 6 weeks of clozapine. Schizophr Res. 2001;48:57-67.
24. Sharma T, Hughes C, Soni W, et al. Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. Psychopharmacology. 2003;169:398-403.
25. Weiner DM, Meltzer HY, Veinbergs I, et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology. 2004;177:207-216.
26. Bondesson U, Lindstrom LH. Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatographyYmass spectrometry with single ion detection. Psychopharmacology. 1988;95:472-475.
27. Perry PJ, Miller DD, Arndt SV, et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry. 1991;148:231-235.
28. Bolden C, Cusack B, Richelson E. Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells. Eur J Pharmacol. 1991;192:205-206.
29. Bymaster FP, Felder CC, Tzavara E, et al. Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1125-1143.
30. Chew ML, Mulsant BH, Pollock BG, et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res. 2006;88:63-72.
31. Miller RJ, Hiley CR. Antimuscarinic properties of neuroleptics and drug-induced parkinsonism. Nature. 1974;248:596-597.
32. Snyder S, Greenber D, Yamamura HI. Antischizophrenic drugs and brain cholinergic receptorsVaffinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry. 1974;31:58-61.
33. Davies MA, Compton-Toth BA, Hufeisen SJ, et al. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M-1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology. 2005;178:451-460.
34. Sur C, Mallorga PJ, Wittmann M, et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA. 2003;100:13674-13679.
35. Hirdes JP. RAI-MH Training Manual and Resource Guide Version 2.0. Toronto, Canada: Ontario Joint Policy and Planning Committee; 2003.
36. Morris JN, Fries BE, Mehr DR, et al. MDS Cognitive Performance Scale. J Gerontol. 1994;49:M174-M182.
37. Paquay L, De Lepeleire J, Schoenmakers B, et al. Comparison of the diagnostic accuracy of the Cognitive Performance Scale (Minimum Data Set) and the Mini-Mental State Exam for the detection of cognitive impairment in nursing home residents. Paper presented at: Meeting of the International Association of Gerontology, European Region; February 17, 2006; Ostend, Belgium.
38. Hartmaier SL, Sloane PD, Guess HA, et al. The MDS cognition scale: a valid instrument for identifying and staging nursing home residents with dementia using the minimum data set. J Am Geriatr Soc. 1994;42:1173-1179.
39. Eiermann B, Engel G, Johansson I, et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol. 1997;44:439-446.
40. Olesen OV, Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol. 2001;41:823-832.
41. Pirmohamed M, Williams D, Madden S, et al. Metabolism and bioactivation of clozapine by human liver in-vitro. J Pharmacol Exp Ther. 1995;272:984-990.
42. Burstein ES, Ma J, Wong S, et al. Intrinsic efficacy of antipsychotics at human D-2, D-3, and D-4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D-2/D-3 partial agonist. J Pharmacol Exp Ther. 2005;315:1278-1287.
43. Kuoppamaki M, Syvalahti E, Hietala J. Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists. Eur J Pharmacol. 1993;245:179-182.
44. Li Z, Huang M, Ichikawa J, et al. N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M-I muscarinic receptors. Neuropsychopharmacology. 2005;30:1986-1995.
45. Homayoun H, Moghaddam B. Fine-tuning of awake prefrontal cortex neurons by clozapine: comparison with haloperidol and N-desmethylclozapine. Biol Psychiatry. 2007;61:679-687.
46. McFarland K, Johnson RW, Son T, et al. N-desmethlyclozapine demonstrated pro-cognitive actions in experimental models. Paper presented at the International Congress on Schizophrenia Research, Colorado Springs, Co; 2007.
47. Gray L, McOmish C, Scarr E, et al. Role of muscarinic receptors in the activity of N-desmethylclozapine: reversal of hyperactivity in the phospholipase C knockout mouse. Paper presented at: European Behavioural Pharmacology Society Workshop on Behavioural Genetics and Neuropsychiatric Disorders; August 25-27, 2008; Cork, Ireland.